Source:http://linkedlifedata.com/resource/pubmed/id/19133710
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2009-1-12
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1173-2563
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
29
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
143-4; author reply 144
|
pubmed:meshHeading |
pubmed-meshheading:19133710-Antipsychotic Agents,
pubmed-meshheading:19133710-Benzodiazepines,
pubmed-meshheading:19133710-Biotransformation,
pubmed-meshheading:19133710-Body Mass Index,
pubmed-meshheading:19133710-Drug Monitoring,
pubmed-meshheading:19133710-Humans,
pubmed-meshheading:19133710-Weight Gain
|
pubmed:year |
2009
|
pubmed:articleTitle |
Body mass index and weight gain as alternative or complementary hypothesis to explain olanzapine concentration-dose ratio accumulation.
|
pubmed:publicationType |
Letter,
Comment
|